Mitesco, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Mitesco, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.7K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $43.7K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $116.0K | Jul 14, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | $3.5K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Apr 17, 2018 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $227.7K | Apr 15, 2015 |
| FY2014 | Dec 31, 2013 | $176.4K | Apr 15, 2015 |
| FY2013 | Dec 31, 2012 | $159.4K | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | $299.1K | Apr 16, 2013 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($339.6K) | Jul 14, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 5, 2022 |
| FY2014 | Dec 31, 2014 | $54.7K | Apr 15, 2015 |
| FY2014 | Dec 31, 2013 | $98.1K | Apr 15, 2015 |
| FY2013 | Dec 31, 2012 | $100.8K | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | $194.8K | Apr 16, 2013 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $498.7K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($2.51M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($13.33M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($23.24M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($7.92M) | Jul 14, 2023 |
| FY2021 | Dec 31, 2020 | ($2.86M) | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | ($3.89M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($1.42M) | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | ($754.0K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($4.88M) | Apr 17, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.88M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($1.16M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($2.59M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($4.33M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($6.40M) | Jul 14, 2023 |
| FY2021 | Dec 31, 2020 | ($2.53M) | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | ($1.44M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($1.32M) | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | ($700.0K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($4.41M) | Apr 17, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.7K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Apr 15, 2026 |
| FY2014 | Dec 31, 2014 | $892.1K | Apr 15, 2015 |
| FY2014 | Dec 31, 2013 | $838.9K | Apr 15, 2015 |
| FY2013 | Dec 31, 2012 | $894.2K | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | $939.6K | Apr 16, 2013 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.69M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.19M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $2.45M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.33M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $6.06M | Jul 14, 2023 |
| FY2021 | Dec 31, 2020 | $2.53M | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | $1.45M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.32M | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $700.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $4.41M | Apr 17, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($701.6K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($514.4K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($759.7K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.17M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($5.00M) | Jul 14, 2023 |
| FY2021 | Dec 31, 2020 | ($1.52M) | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | ($784.5K) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($246.9K) | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | ($47.0K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($269.5K) | Apr 17, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | ($6.8K) | Apr 15, 2015 |
| FY2014 | Dec 31, 2013 | $31.8K | Apr 15, 2015 |
| FY2013 | Dec 31, 2012 | ($16.3K) | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | ($70.8K) | Apr 16, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $132.1K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $189.8K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $2.8K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.60M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $10.65M | Jul 14, 2023 |
| FY2021 | Dec 31, 2020 | $798.5K | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | $100.8K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $3.8K | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.9K | Apr 17, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.60M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $26.61M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $14.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $21.74M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $9.53M | Jul 14, 2023 |
| FY2021 | Dec 31, 2020 | $3.34M | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | $2.42M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.66M | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $1.39M | Apr 1, 2019 |
| FY2016 | Dec 31, 2016 | $1.07M | Apr 17, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.47M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($26.42M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | ($14.13M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | ($19.14M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $1.12M | Apr 16, 2024 |
| FY2022 | Dec 31, 2020 | ($2.54M) | Jul 14, 2023 |
| FY2021 | Dec 31, 2019 | ($2.32M) | Apr 5, 2022 |
| FY2020 | Dec 31, 2018 | ($1.65M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | ($1.39M) | Apr 1, 2020 |
| FY2018 | Dec 31, 2016 | ($1.07M) | Apr 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($63.36M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($63.86M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($62.05M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($48.71M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($25.48M) | Jul 14, 2023 |
| FY2021 | Dec 31, 2020 | ($14.44M) | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | ($11.58M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($7.69M) | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | ($6.28M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($5.52M) | Apr 17, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.9K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $3.4K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $2.8K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $35.6K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.16M | Jul 14, 2023 |
| FY2021 | Dec 31, 2020 | $64.8K | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | $83.2K | Mar 25, 2021 |
| FY2020 | Dec 31, 2018 | $1.3K | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $0 | Apr 1, 2020 |
| FY2018 | Dec 31, 2016 | $0 | Apr 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Jul 14, 2023 |
| FY2019 | Dec 31, 2019 | $199.3K | Apr 1, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Apr 16, 2024 |
| FY2018 | Dec 31, 2018 | 0 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 17, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 31, 2025 |
| FY2018 | Dec 31, 2018 | 0 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 17, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15.09M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 9.76M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 5.57M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 4.63M | Apr 16, 2024 |
| FY2023 | Dec 12, 2022 | 4.63M | Apr 16, 2024 |
| FY2023 | Dec 11, 2022 | 231.37M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 4.27M | Jul 14, 2023 |
| FY2021 | Dec 31, 2020 | 155.38M | Apr 5, 2022 |
| FY2020 | Dec 31, 2019 | 81.27M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 31.60M | Apr 1, 2020 |